Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Klotz, L. et al. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study. Prostate Cancer Prostatic Dis. 17, 320–324 (2014).
2. Bales, G. T. & Chodak, G. W. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 47, 38–43 (1996).
3. Labrie, F., Simard, J., Singh, S. M. & Candas, B. Estimated potency of Casodex: a problematic design. Urology 50, 309–313 (1997).
4. Labrie, F. et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin. Invest. Med. 5, 267–275 (1982).
5. Prostate Cancer Triallists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355, 1491–1498 (2000).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献